Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship
OBJECTIVESTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival. METHODS AND MATERIALSA total of 1240 cases of E...
Gespeichert in:
| Veröffentlicht in: | International journal of gynecological cancer 2015-09, Vol.25 (7), p.1232-1238 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1238 |
|---|---|
| container_issue | 7 |
| container_start_page | 1232 |
| container_title | International journal of gynecological cancer |
| container_volume | 25 |
| creator | Jernigan, Amelia M Mahdi, Haider Rose, Peter G |
| description | OBJECTIVESTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival.
METHODS AND MATERIALSA total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC− based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.
RESULTSOf 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56–78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0–187.91) months. At a median survival of 5.97 (95% CI, 0.20–116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC− to HBOC+ women and did not reveal a significant difference for survival outcomes.
CONCLUSIONSConfirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so. |
| doi_str_mv | 10.1097/IGC.0000000000000489 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1707554413</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1707554413</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4509-53e538b3892e9ff73c77231b8d0b8ab113bd4435ee4f93c648d1591c6d5b4ce33</originalsourceid><addsrcrecordid>eNp9kc9uFSEUxomxsbX6BsaQuHEz7TDADCzrpO1tUq3xT-JuwjBnvFQGboFpc3c-hM_QB-uTyPVWo13IBnL4ne878CH0gpQHpJTN4dlpe1D-vZiQj9Ae4RUvCKPicT7nWiEk-bKLnsZ4mRlZlfIJ2q3qsm5EzfbQ7fHKpCVYoyy-uFbBKIdb5TQE_BaSikklo3HyOEO4BZdCBt9BuPZzxB_XMcGElRuwwidqMnaNFyYmH9a49RsRZ9xXPPqAFxBgMEnlmzcBsu6vrn8d777_OMLvfcoum3E-gM3m3sWlWT1DO6OyEZ7f7_vo88nxp3ZRnF-cnrVH54VmvJQFp8Cp6KmQFchxbKhumoqSXgxlL1RPCO0HxigHYKOkumZiIFwSXQ-8Zxoo3Uevt7qr4K9miKmbTNRgrXKQX9yRpmw4Z4xs0FcP0Es_B5en6yrOK0GlJFWm2JbSwccYYOxWwUz5GzpSdpscu5xj9zDH3PbyXnzuJxj-NP0OLgNiC9x4myDEb3a-gdAtQdm0_L_2T2BOq-E</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552839912</pqid></control><display><type>article</type><title>Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship</title><source>Journals@Ovid Complete - AutoHoldings</source><source>MEDLINE</source><creator>Jernigan, Amelia M ; Mahdi, Haider ; Rose, Peter G</creator><creatorcontrib>Jernigan, Amelia M ; Mahdi, Haider ; Rose, Peter G</creatorcontrib><description>OBJECTIVESTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival.
METHODS AND MATERIALSA total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC− based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.
RESULTSOf 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56–78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0–187.91) months. At a median survival of 5.97 (95% CI, 0.20–116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC− to HBOC+ women and did not reveal a significant difference for survival outcomes.
CONCLUSIONSConfirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1097/IGC.0000000000000489</identifier><identifier>PMID: 26067864</identifier><language>eng</language><publisher>England: by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</publisher><subject>Adenocarcinoma, Clear Cell - genetics ; Adenocarcinoma, Clear Cell - mortality ; Adenocarcinoma, Clear Cell - pathology ; Adenocarcinoma, Clear Cell - therapy ; Adenocarcinoma, Mucinous - genetics ; Adenocarcinoma, Mucinous - mortality ; Adenocarcinoma, Mucinous - pathology ; Adenocarcinoma, Mucinous - therapy ; Adult ; Aged ; Brain Neoplasms - genetics ; Brain Neoplasms - mortality ; Brain Neoplasms - secondary ; Brain Neoplasms - therapy ; Breast cancer ; Cystadenocarcinoma, Serous - genetics ; Cystadenocarcinoma, Serous - mortality ; Cystadenocarcinoma, Serous - pathology ; Cystadenocarcinoma, Serous - therapy ; Endometrial Neoplasms - genetics ; Endometrial Neoplasms - mortality ; Endometrial Neoplasms - pathology ; Endometrial Neoplasms - therapy ; Family medical history ; Female ; Follow-Up Studies ; Genetic disorders ; Genetic Predisposition to Disease ; Genetic Testing ; Humans ; Lymphatic Metastasis ; Metastasis ; Middle Aged ; Mutation ; Mutation - genetics ; Neoplasm Invasiveness ; Neoplasm Staging ; Nervous system ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Prognosis ; Spinal Cord Neoplasms - genetics ; Spinal Cord Neoplasms - mortality ; Spinal Cord Neoplasms - secondary ; Spinal Cord Neoplasms - therapy ; Survival Rate ; Womens health</subject><ispartof>International journal of gynecological cancer, 2015-09, Vol.25 (7), p.1232-1238</ispartof><rights>2015 by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology.</rights><rights>Copyright © 2015 by IGCS and ESGO2015</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4509-53e538b3892e9ff73c77231b8d0b8ab113bd4435ee4f93c648d1591c6d5b4ce33</citedby><cites>FETCH-LOGICAL-c4509-53e538b3892e9ff73c77231b8d0b8ab113bd4435ee4f93c648d1591c6d5b4ce33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26067864$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jernigan, Amelia M</creatorcontrib><creatorcontrib>Mahdi, Haider</creatorcontrib><creatorcontrib>Rose, Peter G</creatorcontrib><title>Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>OBJECTIVESTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival.
METHODS AND MATERIALSA total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC− based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.
RESULTSOf 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56–78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0–187.91) months. At a median survival of 5.97 (95% CI, 0.20–116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC− to HBOC+ women and did not reveal a significant difference for survival outcomes.
CONCLUSIONSConfirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.</description><subject>Adenocarcinoma, Clear Cell - genetics</subject><subject>Adenocarcinoma, Clear Cell - mortality</subject><subject>Adenocarcinoma, Clear Cell - pathology</subject><subject>Adenocarcinoma, Clear Cell - therapy</subject><subject>Adenocarcinoma, Mucinous - genetics</subject><subject>Adenocarcinoma, Mucinous - mortality</subject><subject>Adenocarcinoma, Mucinous - pathology</subject><subject>Adenocarcinoma, Mucinous - therapy</subject><subject>Adult</subject><subject>Aged</subject><subject>Brain Neoplasms - genetics</subject><subject>Brain Neoplasms - mortality</subject><subject>Brain Neoplasms - secondary</subject><subject>Brain Neoplasms - therapy</subject><subject>Breast cancer</subject><subject>Cystadenocarcinoma, Serous - genetics</subject><subject>Cystadenocarcinoma, Serous - mortality</subject><subject>Cystadenocarcinoma, Serous - pathology</subject><subject>Cystadenocarcinoma, Serous - therapy</subject><subject>Endometrial Neoplasms - genetics</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Endometrial Neoplasms - pathology</subject><subject>Endometrial Neoplasms - therapy</subject><subject>Family medical history</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Genetic disorders</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic Testing</subject><subject>Humans</subject><subject>Lymphatic Metastasis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Mutation - genetics</subject><subject>Neoplasm Invasiveness</subject><subject>Neoplasm Staging</subject><subject>Nervous system</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Prognosis</subject><subject>Spinal Cord Neoplasms - genetics</subject><subject>Spinal Cord Neoplasms - mortality</subject><subject>Spinal Cord Neoplasms - secondary</subject><subject>Spinal Cord Neoplasms - therapy</subject><subject>Survival Rate</subject><subject>Womens health</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kc9uFSEUxomxsbX6BsaQuHEz7TDADCzrpO1tUq3xT-JuwjBnvFQGboFpc3c-hM_QB-uTyPVWo13IBnL4ne878CH0gpQHpJTN4dlpe1D-vZiQj9Ae4RUvCKPicT7nWiEk-bKLnsZ4mRlZlfIJ2q3qsm5EzfbQ7fHKpCVYoyy-uFbBKIdb5TQE_BaSikklo3HyOEO4BZdCBt9BuPZzxB_XMcGElRuwwidqMnaNFyYmH9a49RsRZ9xXPPqAFxBgMEnlmzcBsu6vrn8d777_OMLvfcoum3E-gM3m3sWlWT1DO6OyEZ7f7_vo88nxp3ZRnF-cnrVH54VmvJQFp8Cp6KmQFchxbKhumoqSXgxlL1RPCO0HxigHYKOkumZiIFwSXQ-8Zxoo3Uevt7qr4K9miKmbTNRgrXKQX9yRpmw4Z4xs0FcP0Es_B5en6yrOK0GlJFWm2JbSwccYYOxWwUz5GzpSdpscu5xj9zDH3PbyXnzuJxj-NP0OLgNiC9x4myDEb3a-gdAtQdm0_L_2T2BOq-E</recordid><startdate>201509</startdate><enddate>201509</enddate><creator>Jernigan, Amelia M</creator><creator>Mahdi, Haider</creator><creator>Rose, Peter G</creator><general>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201509</creationdate><title>Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship</title><author>Jernigan, Amelia M ; Mahdi, Haider ; Rose, Peter G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4509-53e538b3892e9ff73c77231b8d0b8ab113bd4435ee4f93c648d1591c6d5b4ce33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adenocarcinoma, Clear Cell - genetics</topic><topic>Adenocarcinoma, Clear Cell - mortality</topic><topic>Adenocarcinoma, Clear Cell - pathology</topic><topic>Adenocarcinoma, Clear Cell - therapy</topic><topic>Adenocarcinoma, Mucinous - genetics</topic><topic>Adenocarcinoma, Mucinous - mortality</topic><topic>Adenocarcinoma, Mucinous - pathology</topic><topic>Adenocarcinoma, Mucinous - therapy</topic><topic>Adult</topic><topic>Aged</topic><topic>Brain Neoplasms - genetics</topic><topic>Brain Neoplasms - mortality</topic><topic>Brain Neoplasms - secondary</topic><topic>Brain Neoplasms - therapy</topic><topic>Breast cancer</topic><topic>Cystadenocarcinoma, Serous - genetics</topic><topic>Cystadenocarcinoma, Serous - mortality</topic><topic>Cystadenocarcinoma, Serous - pathology</topic><topic>Cystadenocarcinoma, Serous - therapy</topic><topic>Endometrial Neoplasms - genetics</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Endometrial Neoplasms - pathology</topic><topic>Endometrial Neoplasms - therapy</topic><topic>Family medical history</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Genetic disorders</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic Testing</topic><topic>Humans</topic><topic>Lymphatic Metastasis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Mutation - genetics</topic><topic>Neoplasm Invasiveness</topic><topic>Neoplasm Staging</topic><topic>Nervous system</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Prognosis</topic><topic>Spinal Cord Neoplasms - genetics</topic><topic>Spinal Cord Neoplasms - mortality</topic><topic>Spinal Cord Neoplasms - secondary</topic><topic>Spinal Cord Neoplasms - therapy</topic><topic>Survival Rate</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jernigan, Amelia M</creatorcontrib><creatorcontrib>Mahdi, Haider</creatorcontrib><creatorcontrib>Rose, Peter G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jernigan, Amelia M</au><au>Mahdi, Haider</au><au>Rose, Peter G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>2015-09</date><risdate>2015</risdate><volume>25</volume><issue>7</issue><spage>1232</spage><epage>1238</epage><pages>1232-1238</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>OBJECTIVESTo estimate the frequency of hereditary breast and ovarian cancer (HBOC) in women with central nervous system (CNS) metastasis from epithelial ovarian cancer (EOC) and to evaluate for a potential relationship between HBOC status and survival.
METHODS AND MATERIALSA total of 1240 cases of EOC treated between 1995 and 2014 were reviewed to identify CNS metastasis. Demographics, treatment, family history, genetic testing, and survival outcomes were recorded. Women were then classified as HBOC+ or HBOC− based on histories and genetic testing results. Kaplan-Meier survival curves and univariable Cox proportional hazards models were used.
RESULTSOf 1240 cases, 32 cases of EOC with CNS metastasis were identified (2.58%). Median age was 52.13 (95% confidence interval [CI], 40.56–78.38) years, and 87.10% had stage III to IV disease. Among those with documented personal and family history, 66.7% (20/30) were suspicious for HBOC syndrome. Among those who underwent germline testing, 71.43% (5/7) had a pathogenic BRCA mutation. The median time from diagnosis to CNS metastasis was 29.17 (95% CI, 0–187.91) months. At a median survival of 5.97 (95% CI, 0.20–116.95) months from the time of CNS metastasis and 43.76 (95% CI, 1.54-188.44) months from the time of EOC diagnosis, 29 women died of disease. Univariate Cox proportional hazard models were used to compare HBOC− to HBOC+ women and did not reveal a significant difference for survival outcomes.
CONCLUSIONSConfirmed BRCA mutations and histories concerning for HBOC syndrome are common in women with EOC metastatic to the CNS. We did not demonstrate a relationship between HBOC status and survival outcomes, but were not powered to do so.</abstract><cop>England</cop><pub>by the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology</pub><pmid>26067864</pmid><doi>10.1097/IGC.0000000000000489</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1048-891X |
| ispartof | International journal of gynecological cancer, 2015-09, Vol.25 (7), p.1232-1238 |
| issn | 1048-891X 1525-1438 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1707554413 |
| source | Journals@Ovid Complete - AutoHoldings; MEDLINE |
| subjects | Adenocarcinoma, Clear Cell - genetics Adenocarcinoma, Clear Cell - mortality Adenocarcinoma, Clear Cell - pathology Adenocarcinoma, Clear Cell - therapy Adenocarcinoma, Mucinous - genetics Adenocarcinoma, Mucinous - mortality Adenocarcinoma, Mucinous - pathology Adenocarcinoma, Mucinous - therapy Adult Aged Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - secondary Brain Neoplasms - therapy Breast cancer Cystadenocarcinoma, Serous - genetics Cystadenocarcinoma, Serous - mortality Cystadenocarcinoma, Serous - pathology Cystadenocarcinoma, Serous - therapy Endometrial Neoplasms - genetics Endometrial Neoplasms - mortality Endometrial Neoplasms - pathology Endometrial Neoplasms - therapy Family medical history Female Follow-Up Studies Genetic disorders Genetic Predisposition to Disease Genetic Testing Humans Lymphatic Metastasis Metastasis Middle Aged Mutation Mutation - genetics Neoplasm Invasiveness Neoplasm Staging Nervous system Ovarian cancer Ovarian Neoplasms - genetics Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Prognosis Spinal Cord Neoplasms - genetics Spinal Cord Neoplasms - mortality Spinal Cord Neoplasms - secondary Spinal Cord Neoplasms - therapy Survival Rate Womens health |
| title | Epithelial Ovarian Cancer Metastatic to the Central Nervous System and a Family History Concerning for Hereditary Breast and Ovarian Cancer—A Potential Relationship |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T06%3A03%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Epithelial%20Ovarian%20Cancer%20Metastatic%20to%20the%20Central%20Nervous%20System%20and%20a%20Family%20History%20Concerning%20for%20Hereditary%20Breast%20and%20Ovarian%20Cancer%E2%80%94A%20Potential%20Relationship&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=Jernigan,%20Amelia%20M&rft.date=2015-09&rft.volume=25&rft.issue=7&rft.spage=1232&rft.epage=1238&rft.pages=1232-1238&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1097/IGC.0000000000000489&rft_dat=%3Cproquest_cross%3E1707554413%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552839912&rft_id=info:pmid/26067864&rfr_iscdi=true |